{"filings":[{"id":787477,"accession_number":"0001193125-26-252475","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-06-02T11:05:16+00:00","items":["8.01"],"status":"ready","headline":"Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.","eGFR results now expected in the third quarter of 2026.","Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.","Alignment could accelerate path to full approval for atacicept."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-02","daily_digest_url":"/daily/2026-06-02","daily_digest_rank":7},{"id":669516,"accession_number":"0001193125-26-239559","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-05-26T20:54:31+00:00","items":["5.07"],"status":"ready","headline":"Vera Therapeutics stockholders elect three Class II directors, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael M. Morrisey elected with 45.3M For, 13.8M Withheld; Patrick G. Enright with 54.7M For; James R. Meyers with 58.9M For.","Ratification of KPMG as auditor for FY 2026 approved (61.8M For, 44.7K Against, 87.3K Abstain).","Advisory vote on executive compensation approved (56.6M For, 2.4M Against, 84.3K Abstain, 2.9M Broker non-votes).","71.7M shares outstanding and entitled to vote as of record date March 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95979,"accession_number":"0001193125-26-210351","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.","Cash, equivalents and marketable securities at $596.8M; expects to fund operations beyond expected launch.","FDA accepted atacicept BLA for priority review with PDUFA date of July 7, 2026 for IgAN.","Matt Skelton promoted to CCO; Jane Wright-Mitchell appointed Chief Legal Officer; Christopher Hite added to board.","Initial Phase 2 PIONEER basket trial results expected Q2 2026; pivotal eGFR data from ORIGIN 3 expected Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109454,"accession_number":"0001193125-26-098783","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints Christopher Hite to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Hite appointed as Class III Director effective March 5, 2026.","Initial option grant for 24,937 shares at $38.85, vesting monthly over three years.","Annual cash retainer of $45,000, pro-rated for 2026.","Eligible for annual option grants from 2027: lesser of 18,000 shares or up to $400k in grant date fair value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109453,"accession_number":"0001193125-26-073421","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports FY 2025 net loss $299.6M; FDA priority review for atacicept PDUFA July 7, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.","Cash, equivalents, and marketable securities $714.6M as of Dec 31, 2025, expected to fund through atacicept launch.","FDA granted priority review for atacicept BLA in IgA nephropathy; PDUFA date July 7, 2026.","Completed $800M equity/debt financings; potential U.S. commercial launch mid-2026 if approved.","Appointed James R. Meyers to Board; Phase 2 PIONEER basket trial results expected 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125957,"accession_number":"0001193125-25-323298","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics Announces Departure of Chief Legal Officer Jason Carter","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Carter will cease to be Chief Legal Officer of Vera Therapeutics, effective December 24, 2025.","The departure was announced on December 16, 2025, and filed on Form 8-K.","No reason for the departure was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125956,"accession_number":"0001193125-25-314430","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics prices public offering of 6.14M shares at $42.50, raising ~$260.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered underwriting agreement Dec 9 to sell 6,138,108 shares of common stock at $42.50/share.","Gross proceeds to company approximately $260.9 million before underwriting discounts and expenses.","Underwriters fully exercised 30-day over-allotment option for 920,716 additional shares on Dec 10.","Offering expected to close Dec 11, 2025, subject to customary conditions.","Shares offered under existing automatic shelf registration statement (File No. 333-282861)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125955,"accession_number":"0001193125-25-300647","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints James R. Meyers to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.","Appointed to Audit Committee; received nonstatutory stock option for 25,000 shares vesting monthly over 3 years.","Annual cash retainer of $40k plus $10k Audit Committee retainer, pro-rated for 2025.","Eligible for annual option grant at 2026 meeting: lesser of 14,000 shares or fair value not exceeding $400,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125954,"accession_number":"0001193125-25-268331","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).","Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.","Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.","eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.","Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125953,"accession_number":"0001193125-25-265799","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.","BLA for atacicept in IgA nephropathy under Accelerated Approval submitted to FDA expected Q4 2025.","ORIGIN 3 36-week results presented as late-breaking oral at ASN Kidney Week on Nov 6, 2025.","PIONEER basket trial and ORIGIN Extend study actively enrolling; initial PIONEER data expected Q4 2025.","Potential FDA approval and U.S. commercial launch of atacicept anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142691,"accession_number":"0001193125-25-173591","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.","Prior $200M ATM agreement with TD Cowen terminated effective August 5, 2025.","TD Cowen will receive up to 3.0% commission on gross proceeds of shares sold.","Company not obligated to sell any shares; sales subject to company instructions and market conditions.","Issuance will be made under existing S-3 shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142690,"accession_number":"0000950170-25-102399","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.","Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).","BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.","Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.","Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160763,"accession_number":"0001193125-25-133730","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.","Additional tranches: up to $175M upon milestones, plus $200M uncommitted subject to mutual agreement.","Interest rate: greater of 1-Month Term SOFR + 4.95% and 8.70%; maturity June 2030 or 2031.","Collateral on substantially all assets except IP; financial covenants require minimum liquidity or loan coverage ratios.","Facility fee 0.75% of funded amount; final payment and prepayment fees apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160762,"accession_number":"0001193125-25-132736","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.","Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.","Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.","Trial continues blinded to assess eGFR over two years, expected completion in 2027.","No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160761,"accession_number":"0000950170-25-074446","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders re-elect three Class I directors, ratify KPMG, and approve executive compensation on advisory basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class I directors (Fordyce, Seidenberg, Hall) each with >49M votes for, ~5.4M withheld, and 1.8M broker non-votes.","Ratified KPMG LLP as auditor for FY2025 with 56.6M votes for and only 3,556 against.","Advisory 'Say-on-Pay' approved with 52.98M votes for (96.6% of votes cast).","Stockholders recommended annual advisory vote on executive compensation (54.8M votes for 'One Year'); company to hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160760,"accession_number":"0000950170-25-063975","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.","Cash, equivalents and marketable securities of $589.8M as of March 31, 2025.","Primary endpoint results from atacicept pivotal Phase 3 ORIGIN trial in IgAN expected in 2Q 2025.","BLA submission for atacicept accelerated approval planned for 4Q 2025; potential launch in 2026.","Expanded atacicept program into primary membranous nephropathy, FSGS, and minimal change disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178958,"accession_number":"0000950170-25-027337","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.","Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.","Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.","Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.","FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178957,"accession_number":"0001193125-25-005010","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vera Therapeutics releases corporate presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation furnished as Exhibit 99.1, available on company website.","No specific financial results, guidance, or material events disclosed in the filing.","Presentation contains forward-looking statements as noted in slides."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195645,"accession_number":"0000950170-24-122814","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.","Completed $345M public equity offering to fund atacicept launch and regulatory submission.","Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.","Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.","Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195644,"accession_number":"0001193125-24-248079","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics launches $300M public offering of 7.1M shares at $42.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,142,858 shares offered at $42.00/share; gross proceeds ~$300M before discounts and expenses.","Underwriters have 30-day option to purchase up to 1,071,428 additional shares at the same price.","Closing expected October 31, 2024; J.P. Morgan, Goldman Sachs, Evercore, Cantor Fitzgerald are underwriters.","Offering made under automatic shelf registration statement on Form S-3; customary closing conditions apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195643,"accession_number":"0001193125-24-245704","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.","Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.","Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.","Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.","Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195642,"accession_number":"0001193125-24-230760","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.","PIONEER study in 2025 will evaluate atacicept in expanded IgAN populations (low eGFR, high/low proteinuria, recurrence post-transplant, adolescents) and podocytopathies (pMN, FSGS, MCD).","Combined US peak prevalence of IgAN and autoimmune-driven pMN, FSGS, MCD estimated at ~230,000.","96-week Phase 2b ORIGIN data to be presented as Late Breaking Oral at ASN Kidney Week 2024.","Multiple regulatory and clinical milestones expected over next 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211904,"accession_number":"0000950170-24-093342","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $33.7M; gets FDA Breakthrough Therapy Designation for atacicept in IgAN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.","FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).","Phase 2b ORIGIN data: atacicept stabilized kidney function through 72 weeks, reduced hematuria; 96-week data expected Q4 2024.","Phase 3 ORIGIN 3 enrollment on track to complete Q3 2024; topline data expected Q2 2025.","Appointed David L. Johnson COO, Amit Sharma EVP Medical Affairs; Christy J. Oliger to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211903,"accession_number":"0001193125-24-174318","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints David Johnson as COO effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.","Annual base salary of $500,000; eligible for bonus up to 40% of base salary.","Granted option to purchase 160,000 shares at $36.29, vesting over 4 years.","Severance: 9 months salary without change in control; 12 months with change in control.","Johnson also receives up to $10,000 reimbursement for legal fees related to offer letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230696,"accession_number":"0001193125-24-159935","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints Christy Oliger to board; grants 25K share options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christy Oliger appointed as Class III Director effective June 7, 2024, term through 2027 annual meeting.","Received nonstatutory stock option for 25,000 shares vesting monthly over three years.","Annual cash retainer of $40,000 for board service plus $4,000 for Nominating Committee, prorated for 2024.","Awarded 2,987 restricted stock units, fully vested for prior consulting services, settling in 2025.","Will serve on Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230695,"accession_number":"0000950170-24-061872","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vera Therapeutics stockholders re-elect two Class III directors; ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Andrew Cheng re-elected with 27.4M votes for, 13.0M withheld; Scott Morrison with 31.6M for, 8.8M withheld.","Broker non-votes were 1,020,833 for both director elections.","KPMG ratified as independent auditor for FY2024: 41.4M for, 1,832 against, 7,116 abstain.","Meeting held May 15, 2024; 54,451,375 Class A shares outstanding as of record date March 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230694,"accession_number":"0000950170-24-056283","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.","Cash and equivalents $403.7M after $287.5M financing; runway through approval and launch.","Positive 72-week Phase 2b ORIGIN data; 96-week topline results expected Q4 2024.","Pivotal Phase 3 ORIGIN 3 enrollment estimated complete Q3 2024; data 1H 2025.","Appointed Robert M. Brenner as CMO and William D. Turner as CDO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}